The role of granulocyte-macrophage colony-stimulating growth factor in inflammatory bowel diseases
- 作者: Pershko V.А.1, Yarovenko I.I.1, Pershko А.М.1
-
隶属关系:
- S.M. Kirov Military Medical Academy
- 期: 卷 35, 编号 3 (2024)
- 页面: 12-15
- 栏目: Lecture
- URL: https://journals.eco-vector.com/0236-3054/article/view/629971
- DOI: https://doi.org/10.29296/25877305-2024-03-02
- ID: 629971
如何引用文章
详细
Inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease, are chronic immune-inflammatory diseases of the intestine that are increasing in prevalence and incidence worldwide. They are progressive, with the need for lifelong therapy, a high risk of surgical interventions and a decrease in the quality of life of patients. The results of clinical and population studies indicate that the possibilities of modern therapy for inflammatory bowel diseases have reached their maximum. Its effectiveness in achieving complete clinical and endoscopic remission, despite the use of genetically engineered biological drugs, is estimated at 35-40%, which is obviously insufficient. A possible solution to this problem could be the inclusion of granulocyte-macrophage colony-stimulating factors in treatment regimens for inflammatory bowel diseases in combination with glucocorticosteroids, cytostatics and biological therapy drugs. A review of a number of experimental and clinical studies that confirmed the clinical effectiveness of macrophage growth factors is the subject of this article.
全文:
作者简介
V. Pershko
S.M. Kirov Military Medical Academy
编辑信件的主要联系方式.
Email: persh_v@mail.ru
ORCID iD: 0000-0003-1492-6667
Сandidate of Medical Sciences
俄罗斯联邦, Saint PetersburgI. Yarovenko
S.M. Kirov Military Medical Academy
Email: persh_v@mail.ru
ORCID iD: 0009-0002-7616-9809
Associate Professor, Сandidate of Medical Sciences
俄罗斯联邦, Saint PetersburgА. Pershko
S.M. Kirov Military Medical Academy
Email: persh_v@mail.ru
ORCID iD: 0009-0009-9562-3529
Professor, MD
俄罗斯联邦, Saint Petersburg参考
- Cosnes J., Gower-Rousseau C., Seksik P. et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140 (6): 1785–94. doi: 10.1053/j.gastro.2011.01.055
- Dignass A., Eliakim R., Magro F. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6 (10): 965–90. doi: 10.1016/j.crohns.2012.09.003
- Wright S.S., Trauernicht A., Bonkowski E. et al. Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2018; 66 (5): 767–72. doi: 10.1097/MPG.0000000000001851
- Molodecky N.A., Soon I.S., Rabi D.M. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142 (1): 46–54. doi: 10.1053/j.gastro.2011.10.001
- Rubin G.P., Hungin A.P., Kelly P.J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000; 14 (12): 1553–9. doi: 10.1046/j.1365-2036.2000.00886.x
- Singh S., Fumery M., Sandborn W.J. First- and Second-line Pharmacotherapy for Moderate-severe Ulcerative Colitis. Aliment Pharmacol Ther. 2018; 47 (2): 162–75. doi: 10.1111/apt.14422
- Yang E., Panaccione N., Whitmire N. et al. Efficacy and Safety of Simultaneous Treatment With Two Biologic Medications in Refractory Crohn's Disease. Aliment Pharmacol Ther. 2020; 51 (11): 1031–8. doi: 10.1111/apt.15719
- Першко А.М. Клинико-морфологические варианты неспецифического язвенного колита: прогнозирование течения и подходы к терапии (клинико-экспериментальное исследование). Автореф. Дисс. … д-ра мед. наук. СПб, 2000; 38 с. [Pershko A.M. Kliniko-morfologicheskie varianty nespetsificheskogo yazvennogo kolita: prognozirovanie techeniya i podkhody k terapii (kliniko-eksperimental'noe issledovanie). Avtoref. Diss. … d-ra med. nauk. SPb, 2000; 38 р. (in Russ.)].
- Cleynen I., Boucher G., Jostins L. et al. International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016; 387 (10014): 156–67. doi: 10.1016/S0140-6736(15)00465-1
- Fukuzawa H., Sawada M., Kayahara T. et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003; 312 (4): 897–902. doi: 10.1016/j.bbrc.2003.11.009
- Hansen G., Hercus T.R., McClure B.J. et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008; 134 (3): 496–507. doi: 10.1016/j.cell.2008.05.053
- Sartor R.B. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Prac Gastroenterol Hepatol. 2006; 3 (7): 390–407. doi: 10.1038/ncpgasthep0528
- Bogunovic M., Ginhoux F., Helft J. et al. Origin of the lamina propria dendritic cell network. Immunity. 2009; 31 (3): 513–25. doi: 10.1016/j.immuni.2009.08.010
- Coombes J.L., Siddiqui K.R, Arancibia-Carcamo C.V. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007; 204 (8): 1757–64. doi: 10.1084/jem.20070590
- Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008; 8 (7): 533–44. doi: 10.1038/nri2356
- Martinez-Moczygemba M., Huston D.P. Biology of common β receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol. 2003; 112 (4): 653–65. doi: 10.1016/S0091
- Burbelo P.D., Browne S.K., Sampaio E.P. et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010; 116 (23): 4848–58. doi: 10.1182/blood-2010-05-286161
- Karner J., Meager A., Laan M. et al. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin Exp Immunol. 2013; 171 (3): 263–72. doi: 10.1111/cei.12024
- Hamilton J.A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002; 23 (8): 403–8. doi: 10.1016/s1471-4906(02)02260-3
- Uchida K., Nakata K., Suzuki T. et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009; 113 (11): 2547–56. doi: 10.1182/blood-2009-05-155689
- Denson L.A., Jurickova I., Karns R. et al. Genetic and transcriptomic variation linked to neutrophil granulocyte-macrophage colony-stimulating factor signaling in pediatric Crohn's disease. Inflamm Bowel Dis. 2019; 25 (3): 547–60. doi: 10.1093/ibd/izy265
- Han X., Uchida K., Jurickova I. et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009; 136 (4): 1261–71. doi: 10.1053/j.gastro.2008.12.046
- Nylund C.M., D'Mello S., Kim M.-O. et al. Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J Pediatr Gastroenterol Nutr. 2011; 52 (5): 542–8. doi: 10.1097/MPG.0b013e3181fe2d93
- Tai S., Remark R., Laface I. et al. A5 gm-csf autoantibodies: predictors of crohn’s disease development and a novel therapeutic approach. J Can Assoc Gastroenterol. 2021; 4 (1): 5–6. doi: 10.1093/jcag/gwab002.004
- Porter C.K., Riddle M.S., Gutierrez R.L. et al. PREDICTS study team. Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics. Contemp Clin Trials Commun. 2019; 14: 100345. doi: 10.1016/j.conctc.2019.100345
- Ferguson L.R. Fundamental and Molecular Mechanisms of Mutagenesis. Mutation Research. 2010; 690: 3–11.
- Jurickova I., Collins M.H., Chalk C. et al. Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte–macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity. Clin Exp Immunol. 2013; 172 (3): 455–65. doi: 10.1111/cei.12076
- Samson C.M., Jurickova I., Molden E. et al. Granulocyte-macrophage colony stimulating factor blockade promotes ccr9(+) lymphocyte expansion in Nod2 deficient mice. Inflamm Bowel Dis. 2011; 17 (12): 2443–55. doi: 10.1002/ibd.21672
- Dabritz J., Bonkowski E., Chalk C. et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013; 108 (12): 1901–10. doi: 10.1038/ajg.2013.360
- Gathungu G., Zhang Y., Tian X. et al. Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn's disease. World J Gastroenterol. 2018; 24 (5): 623–30. doi: 10.3748/wjg.v24.i5.623
- Svenson M., Hansen M.B., Ross C. et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 1998; 91 (6): 2054–61.
- Uchida K., Beck D.C., Yamamoto T. et al. GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis. N Engl J Med. 2007; 356 (6): 567–79. doi: 10.1056/NEJMoa062505
- Watanabe M., Uchida K., Nakagaki K. et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007; 581 (doi: 10.1016/j.febslet.2007.04.029): 2017–21. doi: 10.1016/j.febslet.2007.04.029
- Watanabe M., Uchida K., Nakagaki K. et al. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev. 2010; 21 (4): 263–73. doi: 10.1016/j.cytogfr.2010.03.003
- Blech M., Seeliger D., Kistler B. et al. Molecular structure of human GM-CSF in complex with a disease-associated anti-human GM-CSF autoantibody and its potential biological implications. Biochem J. 2012; 447 (2): 205–15. doi: 10.1042/BJ20120884
- Wang Y., Thomson C.A., Allan L.L. et al. Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proc Natl Acad Sci USA. 2013; 110 (19): 7832–7. doi: 10.1073/pnas.1216011110
- Gregersen P.K., Diamond B., Plenge R.M. GWAS implicates a role for quantitative immune traits and threshold effects in risk for human autoimmune disorders. Curr Opin Immunol. 2012; 24 (5): 538–43. doi: 10.1016/j.coi.2012.09.003
- Dieckgraefe B.K., Korzenik J.R. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002; 360 (9344): 1478–80. doi: 10.1016/S0140-6736(02)11437-1
- Korzenik J.R., Dieckgraefe B.K., Valentine J.F. et al. Sargramostim for Active Crohn's Disease. N Engl J Med. 2005; 352 (21): 2193–201. doi: 10.1056/NEJMoa041109
- Xu Y., Hunt N.H., Bao S. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res. 2008; 18 (12): 1220–9. doi: 10.1038/cr.2008.310
- Egea L., Hirata Y., Kagnoff M.F. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol. 2010; 4 (6): 723–31. doi: 10.1586/egh.10.73
- Bernasconi E., Favre L., Maillard M.H. et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010; 16 (3): 428–41. doi: 10.1002/ibd.21072
- Sainathan S.K., Hanna E.M., Gong Q. et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008; 14 (1): 88–99. doi: 10.1002/ibd.20279
- Valentine J.F., Fedorak R.N., Feagan B. et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009; 58 (10): 1354–62. doi: 10.1136/gut.2008.165738
- Osterweil N. Steroids and G-CSF Improve 90-day Survival in Severe Alcoholic Hepatitis. Conference AASLD. November 09, 2022.